Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma [PDF]
, 2007 Background/ Aims: To evaluate the long-term outcome of surgical and non-surgical local treatments of patients with hepatocellular carcinoma (HCC). Methods: We stratified a cohort of 278 HCC patients using six independent predictors of survival according ...
Angelika Schrader +32 more
core +1 more source
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma [PDF]
, 2016 Hepatocellular carcinoma (HCC) responds poorly to conventional systemic therapies. The first-in-class proteasome inhibitor bortezomib has been approved in clinical use for hematologic malignancies and has shown modest activity in solid tumors, including ...
Bogaerts, Eliene +12 more
core +2 more sources
Frontiers in Immunology, 2022 Hepatocellular carcinoma (HCC) remains an important complication of chronic liver disease, especially when cirrhosis occurs. Existing treatment strategies include surgery, loco-regional techniques, and chemotherapy.
M. Sajid, Lianxin Liu, Cheng-song Sun
semanticscholar +1 more source
Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway. [PDF]
, 2015 Tumor recurrence remains an obstacle after liver surgery, especially in living donor liver transplantation (LDLT) for patients with hepatocellular carcinoma (HCC).
Geng, Wei +9 more
core +9 more sources
Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges
Frontiers in Cell and Developmental Biology, 2021 Immune associated cells in the microenvironment have a significant impact on the development and progression of hepatocellular carcinoma (HCC) and have received more and more attention.
Xiaopei Hao +7 more
semanticscholar +1 more source
New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. [PDF]
, 2018 Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections, excessive alcohol consumption, or non ...
Karin, Michael
core +1 more source
Theranostics, 2021 Metabolic reprogramming, especially Warburg effect, is a key event in tumor initiation and progression. ZEB1 plays a vital role in metastasis of various cancers.
Yanming Zhou +15 more
semanticscholar +1 more source
Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]
, 2017 BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo +16 more
core +1 more source
Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center. [PDF]
, 2018 INTRODUCTION AND AIM:Hepatocellular carcinoma (HCC) is the most common type of liver cancer in adults and has seen a rapid increase in incidence in the United States. Racial and ethnic differences in HCC incidence have been observed, with Latinos showing
Kieffer, Dorothy A +3 more
core +1 more source
Immune Checkpoint Inhibitors in the Treatment of HCC
Frontiers in Oncology, 2021 Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often prospers where a chronic liver disease persists, thus leading a strong rationale for immune therapy.
C. Donisi +13 more
semanticscholar +1 more source